Aktienanalyse zu MiniMed Group Inc (MMED)MMEDMiniMed Group Inc

MiniMed Group, Inc. is an insulin delivery company advancing automated therapy for people with diabetes. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear. It operates in the Healthcare sector.

MiniMed Group, Inc. (MMED) is currently priced at $19.71, which is below several analyst price targets, including $28 from Mizuho and $29 from Truist. However, the stock has a low RSI of 44.224, indicating it is not yet oversold, and the recent negative sentiment from investors regarding Medtronic's abandonment of the brand raises concerns. The company is also facing significant net losses, with a net income of -185 million USD in Q4 2026, which poses a risk to its recovery. Therefore, while there is potential for growth, the current market sentiment and financial performance suggest a cautious approach, leading to a recommendation to hold rather than buy.